JaLCDOI 10.18926/AMO/57959
フルテキストURL 74_1_89.pdf
著者 Kada, Akiko| Fukano, Reiji| Mori, Tetsuya| Kamei, Michi| Tanaka, Fumiko| Ueyama, Junichi| Sekimizu, Masahiro| Osumi, Tomoo| Mori, Takeshi| Koga, Yuhki| Ohki, Kentaro| Fujita, Naoto| Mitsui, Tetsuo| Saito, Akiko M.| Hashimoto, Hiroya| Kobayashi, Ryoji|
抄録 No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established. This study is a multicenter, open-label trial to examine the effectiveness and safety of transplantation with reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL. We defined RIC as the administration of fludarabine (30 mg/m2/day) for five days plus melphalan (70 mg/m2/day) for two days and total body irradiation at 4 Gy, followed by allogeneic hematopoietic stem cell transplantation.
キーワード anaplastic large-cell lymphoma relapsed/refractory fludarabine melphalan total body irradiation
Amo Type Clinical Study Protocol
発行日 2020-02
出版物タイトル Acta Medica Okayama
74巻
1号
出版者 Okayama University Medical School
開始ページ 89
終了ページ 94
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2020 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 32099255
JaLCDOI 10.18926/AMO/57722
フルテキストURL 73_6_547.pdf
著者 Yokoyama, Akihiro| Kada, Akiko| Saito, Akiko M.| Sawamura, Morio| Komeno, Takuya| Sunami, Kazutaka| Takezako, Naoki|
抄録 Elderly multiple myeloma (MM) patients, who are generally ineligible for transplantation, have high risks of death and treatment discontinuation, and require a regimen incorporating novel agents that balance safety, tolerability, and efficacy. We evaluated alternating bortezomib-dexamethasone and lenalidomide-dexamethasone treatments administered over a 63-day cycle in transplant-ineligible elderly patients with newly diagnosed MM. Subcutaneous bortezomib 1.3 mg/m2 was administered weekly on Days 1, 8, 15, and 22; oral lenalidomide 15 mg daily on Days 36-56; and oral dexamethasone 20 mg on Days 1, 8, 15, 22, 36, 43, 50, and 57 for 6 cycles. The primary endpoint was the overall response rate.
キーワード bortezomib lenalidomide dexamethasone myeloma
Amo Type Clinical Study Protocol
発行日 2019-12
出版物タイトル Acta Medica Okayama
73巻
6号
出版者 Okayama University Medical School
開始ページ 547
終了ページ 552
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2019 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 31871340
Web of Science KeyUT 000503431400013
JaLCDOI 10.18926/AMO/57379
フルテキストURL 73_5_469.pdf
著者 Yamasaki, Satoshi| Kada, Akiko| Nagai, Hirokazu| Yoshida, Isao| Choi, Ilseung| Saito, Akiko M.| Iwasakia, Hiromi|
抄録 Romidepsin is an important therapeutic option for patients with peripheral T-cell lymphoma (PTCL). However, the timing of romidepsin administration remains controversial. Romidepsin was launched in Japan as a consolidation therapy agent after conventional salvage chemotherapy with gemcitabine, dexamethasone, and cisplatin (GDP). GDP therapy will be administered every 3 weeks. If complete response, partial response, or stable disease is confirmed after 2-4 GDP cycles, romidepsin will be administered every 4 weeks. The primary endpoint is a 2-year progression-free survival rate. Patients participating in this study and undergoing treatment can expect results similar to or better than those of conventional therapies.
キーワード peripheral T-cell lymphoma not otherwise specified angioimmunoblastic T-cell lymphoma gemcitabine cisplatin, romidepsin
Amo Type Clinical Study Protocol
発行日 2019-10
出版物タイトル Acta Medica Okayama
73巻
5号
出版者 Okayama University Medical School
開始ページ 469
終了ページ 474
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2019 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 31649375
Web of Science KeyUT 000491886600014
JaLCDOI 10.18926/AMO/56185
フルテキストURL 72_4_437.pdf
著者 Koga, Yuhki| Baba, Shingo| Fukano, Reiji| Nakamura, Katsumasa| Soejima, Toshinori| Maeda, Naoko| Sunami, Shosuke| Ueyama, Junichi| Mitsui, Tetsuo| Mori, Takeshi| Osumi, Tomoo| Sekimizu, Masahiro| Ohki, Kentaro| Tanaka, Fumiko| Kamei, Michi| Fujita, Naoto| Mori, Tetsuya| Saito, Akiko M.| Kada, Akiko| Kobayashi, Ryoji|
抄録 This trial enrolls patients with untreated Hodgkin’s lymphoma aged<20 years at diagnosis and examines the effects of omitting radiation therapy if the FDG-positron emission tomography (PET) findings after two completed cycles of combination chemotherapy are negative. It thereby aims to determine whether patients who truly require radiation therapy can be identified by FDG-PET. If so, this modality could be used to omit radiation therapy for all other patients, decreasing the risk of serious long-term complications without affecting survival rates. The outcomes of patients for whom FDG-PET is used to assess early treatment response will also be determined.
キーワード Hodgkin’s lymphoma pediatric fludeoxyglucose positron emission tomography
Amo Type Clinical Study Protocol
発行日 2018-08
出版物タイトル Acta Medica Okayama
72巻
4号
出版者 Okayama University Medical School
開始ページ 437
終了ページ 440
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2018 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 30140095
JaLCDOI 10.18926/AMO/56184
フルテキストURL 72_4_431.pdf
著者 Sekimizu, Masahiro| Osumi, Tomoo| Fukano, Reiji| Koga, Yuhki| Kada, Akiko| Saito, Akiko M.| Mori, Tetsuya|
抄録 Crizotinib is an inhibitor of multiple tyrosine kinases, including the anaplastic lymphoma kinase (ALK). Responses to crizotinib have also been reported in patients with ALK-positive anaplastic large-cell lymphoma (ALCL) and solid tumors with ALK-mutation, including neuroblastoma. Optimal treatment for patients with recurrent or refractory ALK-positive ALCL and neuroblastoma has not been established. There is a need to develop new drugs for these patients. The objectives of this trial are to evaluate the tolerability and safety of crizotinib in Japanese patients with recurrent/refractory ALK-positive ALCL or neuroblastoma (phase I) and its efficacy in recurrent/refractory ALK-positive ALCL (phase II).
キーワード crizotinib recurrent refractory anaplastic large cell lymphoma neuroblastoma
Amo Type Clinical Study Protocol
発行日 2018-08
出版物タイトル Acta Medica Okayama
72巻
4号
出版者 Okayama University Medical School
開始ページ 431
終了ページ 436
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2018 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 30140094
JaLCDOI 10.18926/AMO/55863
フルテキストURL 72_2_197_n.pdf
著者 Takase, Ken| Kada, Akiko| Iwasaki, Hiromi| Yoshida, Isao| Sawamura, Morio| Yoshio, Nobuyuki| Yoshida, Shinichiro| Iida, Hiroatsu| Otsuka, Maki| Takafuta, Toshiro| Ogata, Yuko| Suehiro, Youko| Hirabayashi, Yukio| Hishita, Terutoshi| Yoshida, Chikamasa| Ito, Takuo| Hidaka, Michihiro| Tsutsumi, Ikuyo| Saito, Akiko M.| Nagai, Hirokazu|
抄録 Standard therapy for idiopathic thrombocytopenic purpura (ITP) has not been established. We are conducting a multicenter, prospective trial to determine the efficacy and safety of short-term, high-dose dexamethasone therapy in ITP patients aged 18-80 years with platelet counts of <20, 000 /μL, or with <50, 000/ μL and bleeding symptoms. The primary endpoints of this trial are the proportion of responses (complete plus partial response) on day 180 (day 46+180) after the completion of the 46-day high-dose dexamethasone therapy. The results of this investigation of the effectiveness and safety of this regimen will be essential for the establishment of standard therapy for ITP.
キーワード idiopathic thrombocytopenic purpura short-term high-dose dexamethasone therapy open-label single-arm trial
Amo Type Clinical Study Protocol
発行日 2018-04
出版物タイトル Acta Medica Okayama
72巻
2号
出版者 Okayama University Medical School
開始ページ 197
終了ページ 201
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2018 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 29674771